SCHEMBL6768374

SCHEMBL6768374

Fc1ccc(CNc2ccc3oc4ccc(Cl)cc4c3c2)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.44
CYP2C19 P33261 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
PLA2G1B P04054 1/20 0.44
CYP2D6 P10635 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NTRK1 P04629 4/20 0.42
AHR P35869 1/20 0.41
MAPT P10636 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ATM Q13315 1/20 0.41
ALDH1A1 P00352 2/20 0.41
POLB P06746 2/20 0.41
NTRK3 Q16288 1/20 0.40
NTRK2 Q16620 1/20 0.40
GCGR P47871 2/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6768547 0.91 MEN1 (0.51) CYP2C9CYP2C19CYP1A2CYP3A4PLA2G1B
SCHEMBL6494439 0.91 NTRK1 (0.40) CYP2C9CYP2C19CYP1A2CYP3A4PLA2G1B
SCHEMBL6495210 0.86 MEN1 (0.62) CYP2C9CYP2C19CYP1A2CYP3A4PLA2G1B
SCHEMBL6769319 0.86 AHR (0.42) CYP2C9CYP2C19CYP1A2CYP3A4PLA2G1B
SCHEMBL6491396 0.86 MEN1 (0.42) CYP2C9CYP2C19CYP1A2CYP3A4PLA2G1B
SCHEMBL6774671 0.86 NTRK1 (0.38) CYP2C9CYP2C19CYP1A2CYP3A4PLA2G1B
SCHEMBL6768301 0.82 MEN1 (0.43) CYP2C9CYP2C19CYP1A2CYP3A4PLA2G1B
SCHEMBL6768334 0.82 CYP3A4 (0.37) CYP2C9CYP2C19CYP1A2CYP3A4PLA2G1B
SCHEMBL6770100 0.81 KMT2A (0.49) CYP2C9CYP2C19CYP1A2CYP3A4PLA2G1B
SCHEMBL6481651 0.80 EGFR (0.43) CYP2C9CYP2C19CYP1A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 CYP2C9 1728/4885CYP2C19 2948/4885CYP1A2 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.